Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Paul J. Chiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7003-6605; OpenAlex author ID A5068301962; NIH RePORTER profile ID 1880458. Sources: funder_awards.

Their work

Papers
32 (first author 1, last author 10)
Trials
0
Grants
5
Labs led
1
Collaborators
127
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers, 1 grant · 2013: 2 papers, 1 grant · 2014: 2 grants · 2015: 4 papers · 2016: 6 papers · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 grant · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 32

  1. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  2. Corrigendum to "Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer [Cancer Lett. 379 (2016) 1-11]. Co-author DOI 10.1016/j.canlet.2025.217562↗
  3. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Co-author DOI 10.1038/s41421-024-00720-w↗
  4. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Last author DOI 10.1038/s41467-024-47242-3↗
  5. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer Co-author DOI 10.1101/2024.10.20.619300↗
  6. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Co-author DOI 10.1126/sciadv.add6995↗
  7. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Co-author DOI 10.1016/j.molmet.2021.101426↗
  8. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  9. Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15. Last author DOI 10.21873/anticanres.15972↗
  10. The overexpression of long intergenic ncRNA00162 induced by RelA/p65 promotes growth of pancreatic ductal adenocarcinoma. Last author DOI 10.1111/cpr.12805↗
  11. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Co-author DOI 10.1200/po.19.00330↗
  12. Two Birds with One Stone: Therapeutic Targeting of IL1α Signaling Pathways in Pancreatic Ductal Adenocarcinoma and the Cancer-Associated Fibroblasts. First author DOI 10.1158/2159-8290.cd-18-1460↗
  13. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. Last author DOI 10.1038/onc.2017.393↗
  14. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/scitranslmed.aat3487↗
  15. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. Last author DOI 10.1016/j.canlet.2017.09.018↗
  16. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/ncomms14437↗
  17. Inhibition of Pancreatic Cancer by RhIL1RA-Response. Co-author DOI 10.1158/1078-0432.ccr-17-0083↗
  18. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.05.024↗
  19. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation. Co-author DOI 10.1111/jpi.12285↗
  20. IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-16-0438↗
  21. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. Last author DOI 10.1158/1078-0432.ccr-14-3382↗
  22. FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancr… Co-author DOI 10.1158/1078-0432.ccr-15-2380↗
  23. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1078-0432.ccr-15-2780↗
  24. MicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jgg.2015.07.003↗
  25. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Co-author DOI 10.1038/cr.2015.30↗
  26. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. Last author DOI 10.1158/1535-7163.mct-14-0420↗
  27. Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer. Co-author DOI 10.18632/oncotarget.4125↗
  28. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. Co-author DOI 10.1002/emmm.201302507↗
  29. Study human pancreatic cancer in mice: how close are they? Co-author DOI 10.1016/j.bbcan.2012.11.001↗
  30. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ccr.2011.12.006↗
  31. Desensitization of NFκB for overcoming chemoresistance of pancreatic cancer cells to TNF-α or paclitaxel. Co-author PMID 23155247↗
  32. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Last author DOI 10.1093/jnci/djr243↗

Grants 5

  1. The molecular mechanisms of metabolism reprogramming in mutant Kras/Ink4a-driven pancreatic ductal adenocarcinoma R01CA207031↗
  2. Function and Regulation Mechanisms of Polo-like Kinase 3 in Pancreatic Cancer R01CA140410↗
  3. Mechanisms of Overexpressed TrkB in Inducing Pancreatic Cancer Metastasis R01CA142674↗
  4. Mechanisms of RelA Activation in Cancer R01CA097159↗
  5. TAK1 is a Novel Therapeutic Target in Pancreatic Cancer AWARD pancan:2012-paul-chiao-phd-tak1-is-a-novel-therapeutic-target-in-pa

Closest collaborators

The 25 strongest of 127 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianhua Ling · 16 shared papers, 2011–2026 · strength 1.61
  2. Huamin Wang · 12 shared papers, 2012–2026 · strength 1.07
  3. Anirban Maitra · 8 shared papers, 2018–2026 · strength 1.02
  4. Jie Fu · 9 shared papers, 2015–2026 · strength 1.01
  5. Mien‐Chie Hung · 8 shared papers, 2012–2026 · strength 0.92
  6. Haoqiang Ying · 5 shared papers, 2017–2026 · strength 0.69
  7. Jason B. Fleming · 9 shared papers, 2012–2024 · strength 0.66
  8. Dihua Yu · 4 shared papers, 2023–2026 · strength 0.63
  9. Huai‐Qiang Ju · 7 shared papers, 2015–2025 · strength 0.56
  10. Ya’an Kang · 6 shared papers, 2012–2024 · strength 0.52
  11. Ching-Fei Li · 3 shared papers, 2024–2026 · strength 0.51
  12. Yongkun Wei · 3 shared papers, 2024–2026 · strength 0.51
  13. Lu Yu · 5 shared papers, 2017–2024 · strength 0.47
  14. Jun Yao · 4 shared papers, 2017–2024 · strength 0.47
  15. Kenei Furukawa · 3 shared papers, 2020–2024 · strength 0.44
  16. Rui‐Hua Xu · 4 shared papers, 2016–2025 · strength 0.40
  17. Ying‐Nai Wang · 2 shared papers, 2024–2026 · strength 0.37
  18. Li‐Yuan Bai · 2 shared papers, 2024–2026 · strength 0.37
  19. Matthew H. G. Katz · 4 shared papers, 2016–2022 · strength 0.35
  20. Yun‐Xin Lu · 3 shared papers, 2016–2025 · strength 0.35
  21. Ronald Anthony Depinho · 3 shared papers, 2017–2024 · strength 0.31
  22. Peng Huang · 4 shared papers, 2015–2024 · strength 0.29
  23. Mayrim V. Rios Perez · 3 shared papers, 2016–2022 · strength 0.24
  24. David Roife · 3 shared papers, 2016–2022 · strength 0.24
  25. Rosa F. Hwang · 2 shared papers, 2018–2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.